Jeffrey Allen Morris - 11 Aug 2023 Form 4 Insider Report for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)

Role
10%+ Owner
Signature
/s/ Jeffrey Allen Morris
Issuer symbol
PVCT
Transactions as of
11 Aug 2023
Net transactions value
+$700,000
Form type
4
Filing time
14 Aug 2023, 19:07:30 UTC
Previous filing
09 May 2023
Next filing
14 Aug 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PVCT Common Stock 12,000,000 11 Aug 2023 Direct F1
holding PVCT Common Stock 6,500,000 11 Aug 2023 By IRA F2
holding PVCT Series D-1 Convertible Preferred Stock 3,995,747 11 Aug 2023 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PVCT 8% Secured Convertible Promissory Note Award $700,000 244,584 11 Aug 2023 Series D-1 Convertible Preferred Stock 244,584 $2.86 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person has sole voting and dispositive power over 12,000,000 shares of Common Stock.
F2 The reporting person has sole voting and dispositive power over 6,500,000 shares of Common Stock owned through an IRA retirement plan.
F3 The reporting person has sole voting and dispositive power over 3,995,747 shares of Series D-1 Convertible Preferred Stock, convertible into 39,957,470 shares of Common Stock.
F4 The Reporting Person may voluntarily elect to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "Note") at any time while the Note is outstanding into shares of Series D-1 Convertible Preferred Stock, par value $0.001 per share ("Series D-1 Preferred Stock") at a price per share equal to $2.862. The outstanding principal and interest of the Note will automatically convert into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the Note. The Note was issued pursuant to the Issuer's 2022 Financing.
F5 Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").